Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice

Table 1 Clinical characteristics of mice fed experimental diets for 4 or 8 wk

Group	n	Daily food consumption (g)	Liver weight (g)	Hepatic TG (mg/g liver)	Hepatic FFA (mg/g liver)	Serum ALT (IU/L)
MCS 4 wk	6	6.4 ± 0.5	2.3 ± 0.03	102 ± 30	0.82 ± 0.06	30 ± 5.4
MCD + saline 4 wk	8	3.4 ± 0.5b	1.6 ± 0.02b	314 ± 17b	1.24 ± 0.18b	209 ± 30b
MCD + exendin-4 4 wk	8	3.2 ± 0.6	1.3 ± 0.04d	200 ± 40d	1.05 ± 0.11	190 ± 29
MCS 8 wk	6	6.2 ± 0.5	2.2 ± 0.03	43 ± 9	0.64 ± 0.01	32 ± 16
MCD + saline 8 wk	8	3.4 ± 0.4a	1.4 ± 0.04a	137 ± 31a	0.87 ± 0.06a	103 ± 41a
MCD + exendin-4 8 wk	8	3.0 ± 0.6	1.1 ± 0.03c	96 ± 19	0.69 ± 0.06	81 ± 24

^aP < 0.05, vs MCS 8 wk;

^bP < 0.01, vs MCS 4 wk;

^cP < 0.05, MCD + saline 8 wk;

^dP < 0.01, vs MCD + saline 4 wk. TG: Triglyceride; FFA: Free fatty acid; ALT: Alanine aminotransferase; MCS: Methionine-choline-sufficient diet; MCD: Methionine-choline-deficient diet.

Table 2 Effect of exendin-4 on fasting blood glucose, immunoreactive insulin, homeostasis model assessment-insulin resistance

Group	n	Fasting blood glucose (mg/dL)	IRI (ng/dL)	HOMA-IR
MCS 4 wk	6	520 ± 51	19.7 ± 5.4	26.4 ± 8.1
MCD + saline 4 wk	8	126 ± 13a	4.3 ± 1.4a	1.4 ± 0.5a
MCD + exendin-4 4 wk	8	109 ± 7	2.4 ± 0.9b	0.7 ± 0.3b
MCS 8 wk	6	707 ± 99	5.3 ± 3.6	9.4 ± 6.9
MCD + saline 8 wk	8	133 ± 12c	4.2 ± 0.5c	1.4 ± 0.5c
MCD + exendin-4 8 wk	8	94 ± 8.7	1.1 ± 0.2d	0.3 ± 0.04d

^aP < 0.01, vs MCS 4 wk;

^bP < 0.05, vs MCD + saline 4 wk;

^cP < 0.05, vs MCS 8 wk;

^dP < 0.05, vs MCD + saline 8 wk. IRI: Immunoreactive insulin; HOMA-IR: Homeostasis model assessment-insulin resistance; MCS: Methionine-choline-sufficient diet; MCD: Methionine-choline-deficient diet.